25 – Hepatitis B Vaccines

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/B978-0-323-35761-6.00025-0
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Hepatitis B vaccine

  2022cited by this paper
• Antibody Levels and Protection After Hepatitis B Vaccine: Results of a 30-Year Follow-up Study and Response to a Booster Dose.

  2016cited by this paper
• Prevalence of chronic hepatitis B virus (HBV) infection in U.S. households: National Health and Nutrition Examination Survey (NHANES), 1988‐2012

  2016cited by this paper
• A systematic review and meta-analysis of management options for adults who respond poorly to hepatitis B vaccination.

  2015cited by this paper
• Prophylaxis against hepatitis B virus recurrence after liver transplantation: a registry study.

  2015cited by this paper
• NTCP opens the door for hepatitis B virus infection.

  2015cited by this paper
• Genotypes and viral variants in chronic hepatitis B: A review of epidemiology and clinical relevance.

  2015cited by this paper
• Immunogenicity and safety of an investigational hepatitis B vaccine with a Toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared with a licensed hepatitis B vaccine in patients with chronic kidney disease and type 2 diabetes mellitus.

  2015cited by this paper
• Global epidemiology of hepatocellular carcinoma: an emphasis on demographic and regional variability.

  2015cited by this paper
• Induced immunity against hepatitis B virus.

  2015cited by this paper
• Hepatitis B vaccination

  2015cited by this paper
• Immunogenicity of an investigational hepatitis B vaccine with a toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared with a licensed hepatitis B vaccine in subpopulations of healthy adults 18-70 years of age.

  2015cited by this paper
• Nasal Vaccines Against Hepatitis B: An Update.

  2015cited by this paper
• Delta hepatitis within the Veterans Affairs medical system in the United States: Prevalence, risk factors, and outcomes.

  2015cited by this paper
• Clinical relevance of hepatitis B virus variants.

  2015cited by this paper
• Society for Maternal-Fetal Medicine ( SMFM ) Consult Series : # 38 : Hepatitis B in pregnancy screening , treatment , and prevention of vertical transmission Society for Maternal-Fetal Medicine ( SMFM )

  2015cited by this paper
• Impact of the free‐vaccine policy on timely initiation and completion of hepatitis B vaccination in Fujian, China

  2015cited by this paper
• The long-term efficacy, 13-23 years, of a plasma-derived hepatitis B vaccine in highly endemic areas in China.

  2015cited by this paper
• Is hemodialysis a reason for unresponsiveness to hepatitis B vaccine? Hepatitis B virus and dialysis therapy.

  2015cited by this paper
• Variations and mutations in the hepatitis B virus genome and their associations with clinical characteristics.

  2015cited by this paper
• Response to Challenge Dose Among Young Adults Vaccinated for Hepatitis B as Infants: Importance of Detectable Residual Antibody to Hepatitis B Surface Antigen

  2015cited by this paper
• Epidemiology of Acute Hepatitis B in the United States From Population-Based Surveillance, 2006-2011.

  2015cited by this paper
• Enhanced immune response to hepatitis B vaccination through immunization with a Pre-S1/Pre-S2/S Vaccine

  2015cited by this paper
• Outcomes of Infants Born to Women Infected With Hepatitis B

  2015cited by this paper
• Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013.

  2015cited by this paper
• Strategies to control hepatitis B: Public policy, epidemiology, vaccine and drugs.

  2015cited by this paper
• Assessment of acceptability and usability of new delivery prototype device for intradermal vaccination in healthy subjects

  2014cited by this paper
• Immune memory response induced in vitro by recombinant hepatitis B surface antigen challenge 13–18 years after primary vaccination

  2014cited by this paper
• Off-treatment virologic relapse and outcomes of re-treatment in chronic hepatitis B patients who achieved complete viral suppression with oral nucleos(t)ide analogs

  2014cited by this paper
• Commonly Found Variations/Mutations in the HBsAg of Hepatitis B Virus in the Context of Effective Immunization Programs: Questionable Clinical and Public Health Significance

  2014cited by this paper
• Evolution of the Global Burden of Viral Infections from Unsafe Medical Injections, 2000–2010

  2014cited by this paper
• Repeated vaccinations do not improve specific immune defenses against Hepatitis B in non-responder health care workers.

  2014cited by this paper
• Duration of Protection After Infant Hepatitis B Vaccination Series

  2014cited by this paper
• Genotypes and Genetic Variability of Hepatitis B Virus

  2014cited by this paper
• Hepatitis B vaccine by intradermal route in non responder patients: an update.

  2014cited by this paper
• Antiviral therapy for chronic hepatitis B virus infection and development of hepatocellular carcinoma in a US population.

  2014cited by this paper
• Old and new adjuvants for hepatitis B vaccines

  2014cited by this paper
• Reduced Prevalence of HBsAg Variants following a Successful Immunization Program in China

  2014cited by this paper
• Hepatitis B virus PreS/S gene variants: pathobiology and clinical implications.

  2014cited by this paper
• Molecular virology of hepatitis B virus, sub‐genotype C4 in northern Australian Indigenous populations

  2014cited by this paper
• A cohesive European policy for hepatitis B vaccination, are we there yet?

  2014cited by this paper
• Prevention of neonatal hepatitis B virus transmission.

  2014cited by this paper
• Efficacy of Neonatal HBV Vaccination on Liver Cancer and Other Liver Diseases over 30-Year Follow-up of the Qidong Hepatitis B Intervention Study: A Cluster Randomized Controlled Trial

  2014cited by this paper
• Therapeutic vaccines in treating chronic hepatitis B: the end of the beginning or the beginning of the end?

  2014cited by this paper
• A reduction in chronic hepatitis B virus infection prevalence among children in Vietnam demonstrates the importance of vaccination.

  2014cited by this paper
• Hepatitis B immunity in teenagers vaccinated as infants: an Italian 17-year follow-up study.

  2014cited by this paper
• Hepatitis B virus infection.

  2014cited by this paper
• Viral Entry of Hepatitis B and D Viruses and Bile Salts Transportation Share Common Molecular Determinants on Sodium Taurocholate Cotransporting Polypeptide

  2014cited by this paper
• Clinical implications of hepatitis B virus mutations: recent advances.

  2014cited by this paper
• Therapeutic vaccination and immunomodulation in the treatment of chronic hepatitis B: preclinical studies in the woodchuck

  2014cited by this paper
• Maternal transmission risk and antibody levels against hepatitis B virus e antigen in pregnant women.

  2014cited by this paper
• Short duration of lamivudine for the prevention of hepatitis B virus transmission in pregnancy: lack of potency and selection of resistance mutations

  2014cited by this paper
• The roles of hepatitis B virus-encoded X protein in virus replication and the pathogenesis of chronic liver disease

  2014cited by this paper
• Efficacy and effectiveness of infant vaccination against chronic hepatitis B in the Gambia Hepatitis Intervention Study (1986–90) and in the nationwide immunisation program

  2014cited by this paper
• Emerging epidemic of hepatitis C virus infections among young nonurban persons who inject drugs in the United States, 2006-2012.

  2014cited by this paper
• Trends of Acute Hepatitis B Notification Rates in Eastern China from 2005 to 2013

  2014cited by this paper
• Vaccines and the risk of multiple sclerosis and other central nervous system demyelinating diseases.

  2014cited by this paper
• Induction of a robust T- and B-cell immune response in non- and low-responders to conventional vaccination against hepatitis B by using a third generation PreS/S vaccine.

  2014cited by this paper
• Characterization of HIV–HBV coinfection in a multinational HIV-infected cohort

  2013cited by this paper
• Hepatitis B vaccination: a completed schedule enough to control HBV lifelong? Milan, Italy, 17-18 November 2011.

  2013cited by this paper
• Immunogenicity and safety of an investigational hepatitis B vaccine with a Toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared to a licensed hepatitis B vaccine in healthy adults 40-70 years of age.

  2013cited by this paper
• Long-term anti-HBs antibody persistence following infant vaccination against hepatitis B and evaluation of anamnestic response

  2013cited by this paper
• Origins, design and implementation of the China GAVI project.

  2013cited by this paper
• The molecular epidemiology of hepatitis B in the Indigenous people of northern Australia

  2013cited by this paper
• Determinants of Long-term Protection After Hepatitis B Vaccination in Infancy: A Meta-analysis

  2013cited by this paper
• Immunosuppression and HBV Reactivation

  2013cited by this paper
• Prevention of hepatitis B virus–related hepatocellular carcinoma with antiviral therapy

  2013cited by this paper
• Clinical and Epidemiological Aspects of Hepatocellular Carcinoma in Brazil

  2013cited by this paper
• Seroprotection after recombinant hepatitis B vaccination among newborn infants: a review.

  2013cited by this paper
• Antibody persistence and the effect of a booster dose given 5, 10 or 15 years after vaccinating preadolescents with a recombinant hepatitis B vaccine.

  2013cited by this paper
• Safety and Immunogenicity of a Toddler Dose Following an Infant Series of a Hexavalent Diphtheria, Tetanus, Acellular Pertussis, Inactivated Poliovirus, Haemophilus influenzae type b, Hepatitis B Vaccine Administered Concurrently or at Separate Visits With a Heptavalent Pneumococcal Conjugate Vaccin

  2013cited by this paper
• A hepatitis B vaccine with a novel adjuvant.

  2013cited by this paper
• Causes of Death and Characteristics of Decedents With Viral Hepatitis, United States, 2010

  2013cited by this paper
• Immunogenicity and safety of an investigational hepatitis B vaccine with a toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared with a licensed hepatitis B vaccine in patients with chronic kidney disease.

  2013cited by this paper
• The impact of hepatitis B vaccine in China and in the China GAVI Project.

  2013cited by this paper
• Observational Study of Vaccine Efficacy 24 Years after the Start of Hepatitis B Vaccination in Two Gambian Villages: No Need for a Booster Dose

  2013cited by this paper
• Possible origins and evolution of the hepatitis B virus (HBV).

  2013cited by this paper
• Key outcomes and addressing remaining challenges--perspectives from a final evaluation of the China GAVI project.

  2013cited by this paper
• Should Europe have a universal hepatitis B vaccination programme?

  2013cited by this paper
• The hepatitis B vaccine protects re-exposed health care workers, but does not provide sterilizing immunity.

  2013cited by this paper
• Management of severe acute to fulminant hepatitis B: to treat or not to treat or when to treat?

  2012cited by this paper
• Minimization of hepatitis B infection by a 25-year universal vaccination program.

  2012cited by this paper
• Comparison of safety and immunogenicity of two doses of investigational hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide and three doses of a licensed hepatitis B vaccine in healthy adults 18-55 years of age.

  2012cited by this paper
• Challenge with a hepatitis B vaccine in two cohorts of 4-7-year-old children primed with hexavalent vaccines: an open-label, randomised trial in Italy.

  2012cited by this paper
• The National Perinatal Hepatitis B Prevention Program, 1994–2008

  2012cited by this paper
• The Increasing Burden of Mortality From Viral Hepatitis in the United States Between 1999 and 2007

  2012cited by this paper
• Selection of chronic hepatitis B therapy with high barrier to resistance.

  2012cited by this paper
• Tracing hepatitis B virus to the 16th century in a Korean mummy

  2012cited by this paper
• Increased Risk of Acute Hepatitis B among Adults with Diagnosed Diabetes Mellitus

  2012cited by this paper
• Hepatitis B surface antigen-1018 ISS adjuvant-containing vaccine: a review of HEPLISAV™ safety and efficacy

  2011cited by this paper
• GAVI and Hepatitis B immunisation in India

  2011cited by this paper
• Efficacy and safety of subcutaneous human HBV‐immunoglobulin (Zutectra®) in liver transplantation: an open, prospective, single‐arm phase III study

  2011cited by this paper
• Sexually Transmitted Infections and Hepatitis in Men With a History of Incarceration

  2011cited by this paper
• Presence of immune memory and immunity to hepatitis B virus in adults after neonatal hepatitis B vaccination.

  2011cited by this paper
• Antibody levels and immune memory 23 years after primary plasma-derived hepatitis B vaccination: results of a randomized placebo-controlled trial cohort from China where endemicity is high.

  2011cited by this paper
• Establishment and validation of an ELISA for the quantitation of HBsAg in recombinant hepatitis B vaccines.

  2011cited by this paper
• No resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients monoinfected with chronic hepatitis B virus

  2011cited by this paper
• Preparing for the next public debate: universal vaccination against hepatitis B.

  2011cited by this paper
• Elimination of hepatocellular carcinoma and acute hepatitis B in children 25 years after a hepatitis B newborn and catch‐up immunization program

  2011cited by this paper
• Transplacentally Acquired Maternal Antibody against Hepatitis B Surface Antigen in Infants and its Influence on the Response to Hepatitis B Vaccine

  2011cited by this paper

• Seroprevalence of hepatitis B antibodies among international and domestic university students

  2021cites this paper
• A multicenter evaluation of hepatitis B reactivation with and without antiviral prophylaxis after kidney transplantation

  2021cites this paper
• Immunogenicity and safety of a modified three-dose priming and booster schedule for the Hantaan virus vaccine (Hantavax): A multi-center phase III clinical trial in healthy adults.

  2020cites this paper
• Immunisation

  2019cites this paper
• Assessment of the timely administration of the hepatitis B and BCG birth dose and the primary infant vaccination schedule in 2015-2016 in the Mekong Delta, Viet Nam.

  2018cites this paper
• Transcriptome profiling in blood before and after hepatitis B vaccination shows significant differences in gene expression between responders and non-responders.

  2018cites this paper
• Retrospective Analysis of Viral Hepatitis B Incidence in Russia from 2013 to 2017 in the Context of Preventive Vaccination

  2018cites this paper
• Communicable Diseases Intelligence

  year unknowncites this paper